Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients - Wikidata - awgldk - TriplyDB

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

http://www.wikidata.org/entity/Q34042341

about

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy.Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer.Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer The effect of gartanin, a naturally occurring xanthone in mangosteen juice, on the mTOR pathway, autophagy, apoptosis, and the growth of human urinary bladder cancer cell lines Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population.MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer New phosphatidylinositol 3-kinase inhibitors for cancer.Biomarkers for predicting future metastasis of human gastrointestinal tumors.Molecular markers in bladder cancer: Novel research frontiers.The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference.New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population.Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin.Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers.Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.Association between single nucleotide polymorphisms in the PI3K/AKT/mTOR pathway and bladder cancer risk in a sample of Iranian population.miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1.

P2860

Q26749011-006C30B8-E079-4883-ACB0-AF2394397E0B Q34240707-56C9DA5F-BEE9-4A0C-9DAE-B5A4CE62FD3B Q34345248-E0409AB0-1C66-46CD-B228-0C5458347CC0 Q35131862-7EC4B471-D72F-49B4-954F-F96FDB554661 Q36121689-60ABA430-2A5A-4F24-8742-5D31F139223A Q36201710-5352CC97-B21B-4EF5-AEE5-5B0E7351D1C9 Q36772110-8238FB2B-33F4-4A52-8339-37EC3C8DDF01 Q36899375-4DEED03C-E36D-41EE-8BA1-259F643A1E2F Q37244332-EFC516A2-20D3-4DD6-8632-3240B54F56F4 Q37298808-2861EF4E-4661-4327-A3C8-EDC91025287D Q37447740-92C73BE0-8816-4C3B-855B-F110D02E5FCF Q37661175-23A68A86-08E1-4E3E-9B0C-5B6295632210 Q37731815-C97C842C-3427-4301-BAF0-BEBDF1AC1DB2 Q37851994-EC7E74BA-9D35-4F24-97C0-7C4CB514C0AC Q38078237-35647E03-44E2-4C05-908A-8FFCFA242E67 Q38520403-7AE969AB-733C-45F5-8C87-676D83D3C36D Q38664877-1F9A4E26-B53D-4BC5-A0EE-4CCD3F90B8C8 Q38707932-3F959E97-18DA-4E4A-8107-8F4054170506 Q38932242-323207FA-51A8-46A9-ACC9-2906574BA011 Q40126367-466071A6-D00A-4513-AD2F-5F42A055E867 Q41770394-7D35BE54-B4E5-466A-832E-18813578E45A Q41866875-43B22F6F-339C-4AAB-8B75-71CBD6EFEF8C Q42224250-A27FB54D-C511-41C7-81E5-C24D8FD2E645 Q45254443-4EAFD924-D039-4FBA-8B17-EB5F6E87D91D Q47120813-FC89BE41-7EB2-4641-813F-250FA42C919B Q47156338-8E4095F1-2D05-4756-8526-BEDFC74D8DDD Q49333350-40A857CF-7D46-4CAD-AEE9-22BBEBAB50A0 Q49460628-D314D952-9929-42DF-8E58-A6AF360231C5 Q49570244-BCA8118E-5D24-48BC-BC6D-CD328C5FF026 Q54090255-F4867B68-31C2-4C76-9783-553C876500D5

P2860

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

http://www.wikidata.org/entity/Q34042341

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Genetic variations of the PI3K ...... static bladder cancer patients

@ast

Genetic variations of the PI3K ...... static bladder cancer patients

@en

Genetic variations of the PI3K ...... static bladder cancer patients

@nl

type

label

Genetic variations of the PI3K ...... static bladder cancer patients

@ast

Genetic variations of the PI3K ...... static bladder cancer patients

@en

Genetic variations of the PI3K ...... static bladder cancer patients

@nl

prefLabel

Genetic variations of the PI3K ...... static bladder cancer patients

@ast

Genetic variations of the PI3K ...... static bladder cancer patients

@en

Genetic variations of the PI3K ...... static bladder cancer patients

@nl

P1433

Q34042341-272A5D82-0205-4333-96E7-4A791A7FCBFD

P1476

Q34042341-BE74EA9A-D523-490E-9695-E1F336DA17E4

P2093

Q34042341-1434628E-E146-453D-AA72-190F832BEF26

Q34042341-2B96E471-CD01-4CBA-818C-2E63503931F1

Q34042341-2FA51300-BDFE-496D-96AD-5DF75F3B4400

Q34042341-31059407-6D7F-4EA3-B5DF-FD02B0917F4B

Q34042341-45B25067-FE58-4CCA-B761-0159230A01CA

Q34042341-9EE0AE1B-55EB-48A7-8AA1-748E0D5FFE93

Q34042341-A5D58B8B-8280-4704-9880-440704A8EDF2

Q34042341-D4B512B0-A0D7-43B7-ADA2-B306E1CF1692

Q34042341-DA9C3339-8F81-408A-A915-679D8620A571

P2860

Q34042341-096D5CFB-0F9A-476B-9308-546D169673F2

Q34042341-0EA96A75-6B38-4405-BFCE-65E1B05550CD

Q34042341-20B6E4E4-0C81-4146-9AD4-8F70E6FE8D88

Q34042341-26A41BB2-9329-48BA-B21F-5B1F5850BED9

Q34042341-309E929C-E56E-4002-A797-A5044C41C174

Q34042341-4450EC6E-A738-4791-AE30-D4F89A702380

Q34042341-4800B481-9F97-4D81-8674-7BE570E88470

Q34042341-4FB4AD00-3165-4ACF-9972-CD45EF84BB18

Q34042341-60FB3923-203B-418C-8E9D-56D7DFDB3B1E

Q34042341-727C1600-05BA-42F3-BAA8-553CEEA5B498

P304

Q34042341-EE1C02A7-EA73-4713-BA81-70150BCF334B

P31

Q34042341-F74E9F03-8019-4D22-AFDF-F546E1508129

P356

Q34042341-B1789142-14B3-4428-9541-9A62F999F65B

P407

Q34042341-30C761C0-18CE-406A-A763-FBCDBF587117

P433

Q34042341-6974DBF8-49CA-458E-934C-73C3077872FE

P478

Q34042341-45DB9403-BEA9-4DD4-BE8B-4B3E7CA19B0D

P50

Q34042341-C95E131A-7227-449E-8545-E5C86C49D7A0

P577

Q34042341-179FCFCB-37C3-4CF4-874C-11204FFE7C5C

P5875

Q34042341-E8FEA8DE-4973-4E28-A6B3-E84AEBE4694F

P698

Q34042341-0CF9EAE6-C30E-4C99-A4F0-4A287D4E8639

P921

Q34042341-EBF84E2F-1609-42F2-AAEB-350FED1FB7E7

P932

Q34042341-138E3B73-5A88-44DE-8246-A3F4ACE0604A

P356

P1433

P1476

Genetic variations of the PI3K ...... static bladder cancer patients

@en

P2093

Ann M Killary

http://www.w3.org/2001/XMLSchema#string

Colin P Dinney

http://www.w3.org/2001/XMLSchema#string

George L Delclos

http://www.w3.org/2001/XMLSchema#string

H Barton Grossman

http://www.w3.org/2001/XMLSchema#string

Meng Chen

http://www.w3.org/2001/XMLSchema#string

Michelle A T Hildebrandt

http://www.w3.org/2001/XMLSchema#string

Robert M Chamberlain

http://www.w3.org/2001/XMLSchema#string

Xifeng Wu

http://www.w3.org/2001/XMLSchema#string

Zhen Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

Statistical significance for genomewide studies

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

The protein kinase B/Akt signalling pathway in human malignancy

Cancer statistics, 2009

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.

Guidelines on bladder cancer.

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

P304

1387-1391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGQ110

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44655986

http://www.w3.org/2001/XMLSchema#string

P698

20530239

http://www.w3.org/2001/XMLSchema#string

P921

P932

2915631

http://www.w3.org/2001/XMLSchema#string